SCHEMBL3210319

SCHEMBL3210319

COc1cccc(F)c1Cc1cc2cc(Cl)ccc2nc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.39
TLR8 Q9NR97 1/20 0.37
AMY1A P0DUB6 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HTT P42858 1/20 0.36
LCK P06239 2/20 0.36
BTK Q06187 1/20 0.36
TGFBR1 P36897 2/20 0.36
DHPS P49366 2/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3210074 0.92 TLR8 (0.41) DPP4TLR8AMY1ASMN1; SMN2KDM4E
SCHEMBL3215535 0.91 DPP4 (0.39) DPP4TLR8AMY1ASMN1; SMN2KDM4E
SCHEMBL3197519 0.90 TLR8 (0.40) TLR8AMY1AMEN1POLBMAPT
SCHEMBL3197974 0.86 TLR8 (0.54) TLR8MEN1KMT2ARPS6KA2
SCHEMBL3209853 0.83 TLR8 (0.42) TLR8AMY1AMEN1POLBMAPT
SCHEMBL3215454 0.82 TLR8 (0.40) TLR8MEN1POLBMAPTKMT2A
SCHEMBL4718157 0.82 IDO1 (0.49) DPP4TLR8SMN1; SMN2KDM4EMEN1
SCHEMBL3209362 0.82 PDE10A (0.39) TLR8MAPTHTTJAK2JAK3
SCHEMBL4717132 0.81 KDM4E (0.41) SMN1; SMN2KDM4EMEN1POLBMAPT
SCHEMBL3210986 0.80 PDE10A (0.42) SMN1; SMN2KDM4EMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-08-07 US disclosed
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-02-18 US disclosed
EP-1917245-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS Abbott GmbH & Co. KG (DE) 2008-05-07 EP disclosed
WO-2007022946-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS ABBOTT GMBH & CO. KG (DE) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221371-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C DPP4 3542/4885TLR8 3013/4885AMY1A 4292/4885
US-20100041698-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS HTR5A, HTR1A, HTR2C DPP4 3542/4885TLR8 3013/4885AMY1A 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.